Analysis of the tumor microenvironment in ineffective patients of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

被引：0
|
作者：
Kobayashi, Kazufumi
Ogasawara, Sadahisa
Ishino, Takamasa
Unozawa, Hidemi
Nakagawa, Miyuki
Fujiwara, Kisako
Sakuma, Takafumi
Fujita, Naoto
Kanzaki, Hiroaki
Koroki, Keisuke
Nakamura, Masato
Kiyono, Soichiro
Kanogawa, Naoya
Kondo, Takayuki
Saito, Tomoko
Nakagawa, Ryo
Nakamoto, Shingo
Muroyama, Ryosuke
Chiba, Tetsuhiro
Kato, Naoya
机构：
[1] Chiba Univ, Grad Sch Med, Dept Gastroenterol, Chiba, Japan
[2] Chiba Univ, Grad Sch Med, Chiba, Japan
[3] Chiba Univ, Grad Sch Med, Dept Mol Virol, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
468
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
    Chon, Young Eun
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kang, Beodeul
    Ha, Yeonjung
    Kim, Do Young
    Hwang, Seong Gyu
    Chon, Hong Jae
    Kim, Beom Kyung
    CANCER MEDICINE, 2023, 12 (03): : 2731 - 2738
  • [22] Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma
    Manfredi, G. F.
    Fulgenzi, C. A. M.
    D'Alessio, A.
    Celsa, C.
    Stefanini, B.
    Cheon, J.
    Ang, C.
    Marron, T. U.
    Saeed, A.
    Wietharn, B.
    Pressiani, T.
    Pinter, M.
    Scheiner, B.
    Huang, Yi-Hsiang
    Phen, S.
    Naqash, A. Rafeh
    Piscaglia, F.
    Lin, R. Po-Ting
    Lin, C. -yen
    Dalbeni, A.
    Vivaldi, C.
    Masi, G.
    Thimme, R.
    Vogel, A.
    Schonlein, M.
    von Felden, J.
    Schulze, K.
    Wege, H.
    Galle, P. R.
    Kudo, M.
    Rimassa, L.
    Singal, A.
    Sharma, R.
    Cortellini, A.
    Chon, H. Jae
    Burlone, M.
    Pirisi, M.
    Pinato, D. J.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S8 - S9
  • [23] Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.
    Cheon, Jaekyung
    Jung, Sanghoon
    Kang, Beodeul
    Kim, Hyeyeong
    Kim, Chan
    Chon, Hongjae
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Serial Changes of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
    Murata, Yosuke
    Nosaka, Takuto
    Akazawa, Yu
    Tanaka, Tomoko
    Takahashi, Kazuto
    Naito, Tatsushi
    Matsuda, Hidetaka
    Ohtani, Masahiro
    Nakamoto, Yasunari
    CANCERS, 2024, 16 (13)
  • [25] Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tanaka, Takaaki
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Naganuma, Atsushi
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Iijima, Hiroko
    Hiasa, Yoichi
    CANCER MEDICINE, 2022, 11 (20): : 3796 - 3808
  • [26] Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    LIVER CANCER, 2022, 11 (02) : 180 - 181
  • [27] Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma
    D'Alessio, Antonio
    Cammarota, Antonella
    Zanuso, Valentina
    Pressiani, Tiziana
    Personeni, Nicola
    Rimassa, Lorenza
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (09) : 927 - 939
  • [28] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Hongyu Gong
    Siew Chin Ong
    Fan Li
    Zhiying Weng
    Keying Zhao
    Zhengyou Jiang
    Cost Effectiveness and Resource Allocation, 21
  • [29] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
    Hwang, Sang Youn
    Woo, Hyun Young
    Heo, Jeong
    Kim, Hyung Jun
    Park, Young Joo
    Yi, Ki Youn
    Lee, Yu Rim
    Park, Soo Young
    Chung, Woo Jin
    Jang, Byoung Kuk
    Tak, Won Young
    CANCERS, 2024, 16 (04)
  • [30] Regorafenib for patients with progression of advanced hepatocellular carcinoma after treatment with atezolizumab plus bevacizumab: a case series
    Kang, Wendi
    Fu, Hongjiang
    Luo, Yingen
    Noreika, Danielle M.
    Cong, Tianhao
    Li, Hang
    Yang, Zhengqiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 780 - 787
12345